Celera Corporation

Site Impact announces the appointment of Mr. Michael Conway as Chief Technology Officer

Retrieved on: 
Tuesday, October 31, 2023

COCONUT CREEK, Fla., Oct. 30, 2023 /PRNewswire/ -- Site Impact, a company providing multi-channel direct marketing solutions, announced today the appointment of Michael Conway, MBA as Chief Technology Officer.

Key Points: 
  • COCONUT CREEK, Fla., Oct. 30, 2023 /PRNewswire/ -- Site Impact, a company providing multi-channel direct marketing solutions, announced today the appointment of Michael Conway, MBA as Chief Technology Officer.
  • Mr. Conway will be responsible for leading the technology teams, steering transformation initiatives, and ensuring Site Impact remains at the forefront of our industry.
  • In his most recent role as the CTO at Bidtellect, Michael spearheaded the company's Product and Technology Divisions.
  • Site Impact CEO, Jennifer Gressman said, "Mike brings with him a wealth of experience and expertise in the AdTech & MarTech space.

Think Bioscience Appoints Wendy Young, Ph.D., to its Scientific Advisory Board

Retrieved on: 
Monday, October 30, 2023

BOULDER, Colo., Oct. 30, 2023 /PRNewswire/ -- Think Bioscience ("Think"), a Boulder-based synthetic biology company focused on developing small-molecule therapeutics that target "undruggable" proteins, has appointed Wendy Young, Ph.D., to its Scientific Advisory Board. Dr. Young is a seasoned pharmaceutical professional with 30+ years of experience in small molecule research and development

Key Points: 
  • Think Bioscience brings on accomplished biotech executive and drug discovery veteran Wendy Young, Ph.D.
    BOULDER, Colo., Oct. 30, 2023 /PRNewswire/ -- Think Bioscience ("Think"), a Boulder-based synthetic biology company focused on developing small-molecule therapeutics that target "undruggable" proteins, has appointed Wendy Young , Ph.D., to its Scientific Advisory Board.
  • "We are excited to leverage her deep expertise to build Think into an industry-leading research and development organization."
  • Dr. Young currently serves as a director and/or scientific advisor to several biotech companies and is an advisor at Google Ventures.
  • "I'm excited by the elegance of the Think Bioscience platform, which can discover new functional binding sites and access novel chemical matter.

Analog Heavyweights Join Celera Technologies to Lead Next Phase of Growth

Retrieved on: 
Thursday, October 19, 2023

Analog heavyweights join Celera to bring a new, automated way of designing custom analog chips to the market.

Key Points: 
  • Analog heavyweights join Celera to bring a new, automated way of designing custom analog chips to the market.
  • "Pat and Alberto's deep experience delivering innovative solutions to the analog IC market is exactly what Celera needs to move to its next phase of growth," said Steve O'Hara, Managing Partner at Valley Capital Partners and lead investor for Celera.
  • Celera's patented ChipHUB combines proprietary AI algorithms with decades of analog design experience to deliver a fundamentally new, algorithmic way of designing and delivering analog chips.
  • "I am excited to lead Celera in its next phase of growth," said Brockett.

Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO

Retrieved on: 
Tuesday, October 10, 2023

CINCINNATI, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV), which is focused on developing and commercializing transformational therapies to address significant global health challenges, today announced the appointments of Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO, effective immediately.

Key Points: 
  • CINCINNATI, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV), which is focused on developing and commercializing transformational therapies to address significant global health challenges, today announced the appointments of Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO, effective immediately.
  • James Sapirstein, Blue Water Biotech’s Lead Independent Director, said, "Neil is an exceptional businessman and leader who is well-suited for Blue Water Biotech.
  • Immediately prior to joining Blue Water Biotech, he was an independent consultant who served in the outsourced CFO capacity for multiple publicly traded companies since 2008.
  • During this time, Mr. Harmon was CFO of Marizyme Inc., the CFO of bioAffinity Technologies Inc. and a director of Dale Biotech LLC.

Rapport Therapeutics Appoints Chief Operating Officer and Scientific Advisory Board Member

Retrieved on: 
Thursday, September 7, 2023

Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced the appointment of Cheryl Gault as Chief Operating Officer and Wendy Young, Ph.D., as a member of its Scientific Advisory Board.

Key Points: 
  • Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced the appointment of Cheryl Gault as Chief Operating Officer and Wendy Young, Ph.D., as a member of its Scientific Advisory Board.
  • Ms. Gault comes to Rapport from Cyclerion Therapeutics, where she was Chief Operating Officer overseeing corporate and business development, portfolio strategy, new product planning and corporate strategy functions.
  • Ms. Gault also served at Genzyme Corporation in a variety of sales and marketing roles in the biosurgery division.
  • She currently serves on the boards of directors and scientific advisory boards of several biotech companies and is an advisor at Google Ventures.

DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board

Retrieved on: 
Tuesday, June 13, 2023

DEM BioPharma, Inc. (DEM Bio), an immune-oncology company developing therapies that target signals on cancer cells and myeloid phagocytes to eliminate cancer, today announced the addition of Wendy Young, Ph.D., to its Scientific Advisory Board.

Key Points: 
  • DEM BioPharma, Inc. (DEM Bio), an immune-oncology company developing therapies that target signals on cancer cells and myeloid phagocytes to eliminate cancer, today announced the addition of Wendy Young, Ph.D., to its Scientific Advisory Board.
  • “DEM Bio’s work developing immunotherapeutics to target novel innate immune system checkpoints has the potential to revolutionize cancer therapies,” said Dr. Young.
  • “I am proud to be joining such an impressive team of industry experts and scientists dedicated to eliminating cancer.”
    Wendy currently serves as an Advisor to Google Ventures, Board Director and Scientific Advisory Board Member of several biotech companies.
  • Wendy received a Ph.D. in chemistry from Princeton University and was an American Cancer Society Postdoctoral Fellow at Sloan-Kettering Cancer Center.

Acurex Biosciences Appoints Esteemed Biopharmaceutical Leader Dr. Robert Booth to its Board of Directors

Retrieved on: 
Tuesday, May 30, 2023

Acurex Biosciences Corporation, a biopharmaceutical company with a mission to stop neurodegeneration before it begins, announces the appointment of renowned biopharmaceutical industry leader Dr. Robert Booth to its Board of Directors.

Key Points: 
  • Acurex Biosciences Corporation, a biopharmaceutical company with a mission to stop neurodegeneration before it begins, announces the appointment of renowned biopharmaceutical industry leader Dr. Robert Booth to its Board of Directors.
  • This groundbreaking inhibitor was later licensed to Pharmacyclics, where Dr. Booth served on the Board of Directors until its acquisition by AbbVie.
  • On his appointment to Acurex’s board, Dr. Booth commented, "I am truly excited to join the board of Acurex Biosciences.
  • We are thrilled to be able to attract such an esteemed industry leader and welcome Dr. Booth to our Board of Directors."

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022

Retrieved on: 
Thursday, March 9, 2023

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the fourth quarter and year ended December 31, 2022.
  • Summit is initiating development activities for SMT112 and will do so first in non-small cell lung cancer (NSCLC) indications.
  • Summit intends to start treating patients in clinical studies during the second quarter of 2023.
  • Summit’s management team will host an earnings call to discuss its fourth quarter 2022 financial results and provide an operational update for the Company today, March 9, 2023, at 9:00am ET.

Personalis Grows Leadership Team with Appointment of Christopher Hall as Senior Vice President and Head, Diagnostics Business

Retrieved on: 
Monday, October 31, 2022

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the appointment of Christopher Hall as SVP and Head, Diagnostics Business.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the appointment of Christopher Hall as SVP and Head, Diagnostics Business.
  • As part of the executive leadership team, Hall will drive the vision and strategy for commercializing Personalis diagnostic product offerings.
  • We are excited to welcome Chris given his immense experience in successfully scaling diagnostics businesses, said John West, CEO of Personalis.
  • Hall holds BA in political science and economics from DePauw University and an MBA from Harvard Business School.

Summit Therapeutics Appoints Dr. Robert Booth, Renowned Executive and Scientific Leader, to its Board of Directors

Retrieved on: 
Monday, October 3, 2022

Menlo Park, California, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that Dr. Robert Booth, PhD,has been appointed to its Board of Directors, effective immediately.

Key Points: 
  • Menlo Park, California, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that Dr. Robert Booth, PhD,has been appointed to its Board of Directors, effective immediately.
  • He has over 30 years of experience in the biopharmaceutical industry from executive positions to research and scientific leadership primarily focusing in the areas of oncology, inflammation, and autoimmune disease.
  • He is the co-founder of CuraSen Therapeutics, Inc. where he was previously the Executive Chairman and currently serves as an advisor.
  • Dr. Booth currently serves on the board of Thryv Therapeutics Inc.; he previously served on the boards of Pharmacyclics, Inc., and CymaBay Inc.